TuHURA Appoints Ex-JNJ CMO to Lead TBS-2025 VISTA AML Program
TuHURA Biosciences appointed Dr. Craig L. Tendler as strategic CMO to oversee its VISTA inhibiting antibody TBS-2025 program in AML after receiving preliminary FDA feedback on its early development plan. Tendler’s track record includes coordinating 30 oncology approvals and four cell therapies generating over $16 billion in sales.
1. Leadership Appointment
TuHURA Biosciences appointed Dr. Craig L. Tendler to provide strategic and operational services equivalent to a CMO while remaining on the board. He will oversee clinical development strategy and operations across the company’s pipeline.
2. VISTA Program Details
Dr. Tendler will direct the VISTA inhibiting antibody TBS-2025 in NPM1 mutated AML, leveraging preliminary feedback from the FDA’s Division of Hematologic Malignancies I. He will guide monotherapy and combination trial designs with menin inhibitors.
3. Track Record Impact
Tendler brings 29 years of drug development experience, having coordinated over 30 oncology regulatory approvals and 15 new medical entity approvals, including four biologic or cell therapies that now generate more than $16 billion in annual sales, supporting TuHURA’s clinical advancement efforts.